Définition et prise en charge de l’échec d’une première injection de toxine botulique Botox® 200 U pour hyperactivité détrusorienne neurogène : résultats de l’enquête DETOX
暂无分享,去创建一个
G. Amarenco | X. Gamé | P. Mouracade | A. Ruffion | V. Phé | G. Karsenty | E. Castel-Lacanal | M. Damphousse | E. Chartier-Kastler | P. Denys | A. Manunta | L. Normand | B. Peyronnet | M. Sèze | J. Kerdraon | V. Forin | J. Prévinaire | A. Even | B. Schurch | K. Charvier | C. Saussine | S. Sanson | Xavier Gamé | G. Egon | C.-M. Loche
[1] P. Marque,et al. Preliminary results of botulinum toxin A switch after first detrusor injection failure as a treatment of neurogenic detrusor overactivity , 2016, Neurourology and urodynamics.
[2] A. Guinet-Lacoste,et al. Ancienneté de la neurovessie et efficacité d’une première injection de toxine botulique intradétrusorienne , 2015 .
[3] S. Han,et al. Preoperative urodynamic factors predicting outcome of botulinum toxin-A intradetrusor injection in children with neurogenic detrusor overactivity. , 2014, Urology.
[4] A. Nambiar,et al. Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO) , 2014, Neurourology and urodynamics.
[5] J. Cornu,et al. Les médicaments de la vessie , 2013 .
[6] G. Karsenty,et al. Five years follow-up study and failures analysis of Botulinum toxin repeated injections to treat neurogenic detrusor overactivity. , 2012, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.
[7] M. Brin,et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. , 2012, The Journal of urology.
[8] S. Biers,et al. The past, present and future of augmentation cystoplasty , 2012, BJU international.
[9] M. Brin,et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. , 2011, European urology.
[10] P. Dasgupta,et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). , 2011, European urology.
[11] J. Gajewski,et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. , 2011, The Journal of urology.
[12] X. Gamé,et al. Chapitre C-2 C - Traitement de l’hyperactivité détrusorienne neurologique : entérocystoplasties , 2007 .
[13] L. Brundin,et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity , 2007, Scandinavian journal of urology and nephrology.
[14] C. Heneghan,et al. Levels of Evidence , 2006 .
[15] M. Brin,et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. , 2005, The Journal of urology.
[16] B. Schurch,et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. , 2000, The Journal of urology.